Lyra Therapeutics Inc
NASDAQ:LYRA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Lyra Therapeutics Inc
Lyra Therapeutics Inc
Cash & Cash Equivalents
Lyra Therapeutics Inc
Cash & Cash Equivalents Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
Cash & Cash Equivalents
$22.4m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$7.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$719m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is Lyra Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
22.4m
USD
Based on the financial report for Dec 31, 2023, Lyra Therapeutics Inc's Cash & Cash Equivalents amounts to 22.4m USD.
What is Lyra Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-1%
Over the last year, the Cash & Cash Equivalents growth was -31%. The average annual Cash & Cash Equivalents growth rates for Lyra Therapeutics Inc have been -33% over the past three years , -1% over the past five years .
You don't have any saved screeners yet
